S.Biomedics

S.Biomedics is a South Korean biotechnology company specializing in the research and development of cell therapies for regenerative medicine. The company leverages two proprietary core platform technologies: its Targeted Embryonic stem cell Differentiation (TED) technology and its 3D cell spheroid formation (FECS) technology. By integrating these platforms, S.Biomedics develops a diverse pipeline of cell therapy products designed to treat intractable diseases, including Parkinson's disease, spinal cord injuries, macular degeneration, and stroke. The company maintains GMP-certified manufacturing facilities and operates multiple clinical-stage programs.

These therapies are significant for patients suffering from conditions that currently lack effective treatments. S.Biomedics focuses on translating academic research into clinical applications, supported by years of internal development and numerous patent applications. The company collaborates with global partners, such as Catalent, to scale its manufacturing capabilities and support pivotal clinical studies. By addressing technical challenges in stem cell differentiation and therapy, S.Biomedics aims to deliver innovative, science-driven treatment options for diseases with high unmet medical needs.